ZipurskyA. Transient leukemia—a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003;120:930-938.
2.
GosaviAVMurarkarPSLanjewarDNRavikarRV. Tranisent leukemia in Down syndrome: report of two cases with review of literature. Indian J Hematol Blood Transfus. 2011;27:172-176.
3.
McElwaineSMulliganCGroetJ. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukemia (M7) in Down’s syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol. 2004;125:729-742.
4.
Al-KasimFDoyleJJMasseyGVWeinsteinHJZipurskyA. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2002;24:9-13.
5.
GamisASAlonzoTAGerbingRB. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood. 2011;118:6752-6759.
6.
XuGNaganoMKanezaki. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood. 2003;102:2960-2968.
7.
ChoiJK. Hematopeoietic disorders in Down syndrome. Int J Clin Exp Pathol. 2008;1:387-395.
8.
MalingeSIzraeliSCrispinoJD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood. 2009;113:2619-2628.
9.
HenryEWalkerDWiedmeierSEChristensenRD. Hematological abnormalities during the first week of life among neonates with Down syndrome: data from a multihospital healthcare system. Am J Med Genet A. 2007;143:42-50.
10.
RoizenNJAmaroseAP. Hematologic abnormalities in children with Down syndrome. Am J Med Genet. 1993;46:510-512.
11.
CarpenterEValverde-GardunoVSternbergA. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol. 2004;128:548-551.
12.
OehlerVGGuthrieKACummingsCL. The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic leukemic progenitor cells. Blood. 2009;114:3299-3308.
13.
GuinnBMohamedaliAMillsKICzepulkowskiBSchmittMGreinerJ. Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia. Biomark Insights. 2007;2:69-79.
14.
TaketaniTTakiTTakitaJ. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome. Leukemia. 2002;16:1866-1867.
15.
McLornanDPercyMMcMullinMF. JAK2 V617F: a single mutation in the myeloproliferative group of disorders. Ulster Med J. 2006;75:112-119.
16.
DormannSKrugerMHentschelR. Life-threatening complications of transient abnormal myelopoiesis in neonates with Down syndrome. Eur J Pediatr. 2004;163:374-377.
17.
WebbDKH. Optimizing therapy for myeloid disorders of Down syndrome. Br J Haematol. 2005;131:3-7.
